Active study protocols of the GLSG
First Line Therapy
CHOP + anti CD20 Trial (patients < 60 years)
Therapy of follicular, mantle cell and lymphoplasmocytoid lymphoma in advanced stages: Prospective randomised test of the curative potential of myeloablative radiochemotherapy with autologous PBSCT in comparison to interferon alpha maintenance after initial cytoreductive chemotherapy (CHOP vs CHOP + antiCD20 (rituximab).
European MCL Network Trial (patients < 65 years)
Efficacy of 6 courses CHOP plus Rituximab followed by myeloablative radiochemotherapy and autologous stem cell transplantation versus alternating courses of 3x CHOP and 3x DHAP plus Rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation
European MCL Network Trial (patients > 65 years)
Efficacy of maintenance therapy with rituximab after induction chemotherapy (R-CHOP vs. R-FC) for elderly patients with mantle cell lymphoma not suitable for autologous stem cell transplantation
Relapsed Lymphoma
GO Trial
Multicenter phase I/II study of the German Low Grade Lymphoma Study Group to evaluate the efficacy of a combined Gemcitabine/Oxaliplatinum therapy in patients with relapsed indolent lymphoma.
FC-Campath Trial
Multi center phase II trial fo Fludarabine /Cyclophosphamide in combination with Campath-1H in patients with relapsed follicular and mantle cell lymphoma
90Y-Radioimmunotherapy
Efficacy and safety of 90Y-Ibritumomab tiuxetan in patients with refractory or relapsed mantle cell lymphoma after/not appropriate for autologous stem cell transplantation
Allogeneic Stem Cell Transplantation in Follicular and Mantle Cell Lymphoma
Prospective multicenter phase II study of the German Low Grade Lymphoma Study Group, the European MCL Network and the EBMT lymphoma working group: Allogeneic stem cell transplantation with dose reduced coditioning in patients with relapsed follicular and mantle cell lymphoma.
Navigation
Clinical Trials & Study Groups
Foerderer, Partner und Zertifikate
,
,
